CD44 and cancer: As CD44 is a stemness marker and is known to be associated with EMT32, and because we found that the expression of CD44 was reduced by NS1643 treatment (Fig. 3a & b), we speculated that NS1643 suppresses EMT, which in turn attenuates cancer stemness, thereby inhibiting breast tumor growth and metastasis.